• The patient has read, understood, signed, and dated the Patient Information Sheet with the informed consent form.

• The patient is aged between 35 and 59 years inclusive at the time of signing the Patient Information Sheet with the informed consent form.

• The diagnosis of chronic migraine according to the clinical guidelines on migraine by the Ministry of Health of the Russian Federation (2021) / ICD-10 (2018), established at least 12 months before screening.

• Resistant nature of the migraine, determined by the doctor using the criteria of the European Headache Federation (EHF, 2020), established at least 6 months before screening.

• At least 14 days of headache during the screening period (28 days), of which 8 days of headache meet the definition of migraine (assessed based on the results of filling out the Headache Diary for 28 days during the screening period).

• Migraine, resistant to both pharmacological and non-pharmacological prevention and treatment methods, in the patient's history.

• Maximum level of headache during migraine days above 5 points (inclusive) on a 10-point numerical rating scale during the screening period.

• No positive effect on migraine symptoms (frequency and intensity of headache attacks) from previous botulinum toxin therapy (administration of OnabotulinumtoxinA, Relatox® (botulinum toxin type A - hemagglutinin complex 155 - 195 IU, administered every 12 weeks according to the PREEMPT protocol).

• Consent to use adequate contraceptive methods\* and not serve as an egg/sperm donor from the time of signing the Patient Information Sheet with the informed consent form for participation in the study until the end of the study (for women with reproductive potential and men).